Hepatocyte Specific Antigen antibody (HSA) is considered very specific for normal and neoplastic hepatocytes. Expression has been demonstrated consistently in the majority of hepatocellular carcinomas. Studies have shown HSA to be an effective marker that may be used in a panel with CEA (Carcinoembryonic Antigen), CK7, AFP (Alpha Fetoprotein) and CD10 to aid in the differential diagnosis of hepatocellular carcinoma from cholangiocarcinoma and/or metastatic adenocarcinoma.
1. Maitra A, Murakata LA, Albores-Saavedra J. Immunoreactivity for hepatocyte paraffin 1 antibody in hepatoid adenocarcinomas of the gastrointestinal tract. Am J Clin Pathol. 2001 May;115(5):689-94.
2. S-Y Xiao, et al. CD10/CALLA expression in Hepatocellular carcinoma: A useful Marker for Differential Diagnosis. Abstract 1209, United States and Canadian Academy of Pathology Annual Meeting; March 2001.
3. Fasano M, et al. Immunohistochemical evaluation of hepatoblastomas with use of the hepatocyte-specific marker, hepatocyte paraffin 1, and polyclonal CEA. Mod Pathol. 1998 Oct;11(10):934-8.
4. Leong AS, et al. Hep Par 1 and selected antibodies in the immunohistological distinction of hepatocellular carcinoma from cholangio-carcinoma, combined tumours and metastatic carcinoma. Histopathology. 1998 Oct;33(4):318-24.
5. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 “Decontamination of Laboratory Sink Drains to Remove Azide Salts.”
6. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory workers from occupationally Acquired Infections; Approved guideline-Third Edition CLSI document M29-A3 Wayne, PA 2005.